Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
CH0461929603
Thu, 01.12.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CEST
Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and curasan (a l [ … ]
Thu, 01.12.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies 01.12.2022 / 07:01 CET/CEST
Lysatpharma, a portfolio company of Xlife Sciences (SIX: XLS), and Novaxomx, a joint-venture of Xlife Sciences and curasan (a l [ … ]
Mon, 28.11.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
alytas therapeutics collaborates with spin-off from the German Diabetes Center
28.11.2022 / 07:00 CET/CEST
Xlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of morbid obes [ … ]
Mon, 28.11.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
alytas therapeutics collaborates with spin-off from the German Diabetes Center
28.11.2022 / 07:00 CET/CEST
Xlife Sciences’ (SIX: XLS) portfolio company alytas therapeutics (located in Jena, Germany) explores innovative, antibody-based therapeutic concepts for treatment of morbid obes [ … ]
Tue, 01.11.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
ProcCluster® from portfolio company inflamed pharma granted US patent
01.11.2022 / 07:00 CET/CEST
Xlife Sciences AG (SIX: XLS) announced today that its portfolio company inflamed pharma has been granted a patent by the United States Patent and Trademark Office (USPTO) for the manu [ … ]
Tue, 01.11.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
ProcCluster® from portfolio company inflamed pharma granted US patent
01.11.2022 / 07:00 CET/CEST
Xlife Sciences AG (SIX: XLS) announced today that its portfolio company inflamed pharma has been granted a patent by the United States Patent and Trademark Office (USPTO) for the manu [ … ]
Mon, 26.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Project company Laxxon Medical achieves major milestone
26.09.2022 / 07:00 CET/CEST
Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms
Strengthening the Position of Laxxon Medical’s Intellectual Property in the Pharmaceutical Marke [ … ]
Mon, 26.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Project company Laxxon Medical achieves major milestone
26.09.2022 / 07:00 CET/CEST
Granted U.S. Patent for the Sequential Release of Multiple Drugs Within Pharmaceutical Dosage Forms
Strengthening the Position of Laxxon Medical’s Intellectual Property in the Pharmaceutical Marke [ … ]
Wed, 21.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Xlife Sciences strengthens sustainability activities with ESG strategy
21.09.2022 / 07:00 CET/CEST
One of the objectives of Xlife Sciences (SIX: XLS) is to significantly strengthen and further develop its existing sustainability activities on a strategic and operational level. For th [ … ]
Wed, 21.09.2022
Xlife Sciences AG
Xlife Sciences AG
/ Key word(s): Miscellaneous
Xlife Sciences strengthens sustainability activities with ESG strategy
21.09.2022 / 07:00 CET/CEST
One of the objectives of Xlife Sciences (SIX: XLS) is to significantly strengthen and further develop its existing sustainability activities on a strategic and operational level. For th [ … ]